about
Safety of Oral Amphetamine Administered during Positron Emission Tomography Scans in Medically Screened Humans[11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levelsA comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatumImproved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation.Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients.Neuroreceptor imaging in psychiatric disorders.Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa.Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907Cortical Dopamine Transmission as Measured with the [11C]FLB 457 - Amphetamine PET Imaging Paradigm Is Not Influenced by COMT GenotypeImaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C]NPA positron emission tomography studyNeuroreceptor imaging in psychiatry: theory and applications.Neuroreceptor imaging studies in schizophrenia.Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study.In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET.Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [11 C]PBR28.Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection.Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior.Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans.Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652.COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET.An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.The synaptic hypothesis of schizophrenia.Comment on Analyses and Conclusions of "Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study".Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.Clinical characteristics, cognitive functioning, and criminal histories of outpatients with schizophreniaMeasurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidoneHuman biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ)Failure to detect amphetamine-induced dopamine release in the cortex with [11 C]FLB 457 positron emission tomography (PET): Methodological considerations
P50
Q28551614-2ED1E124-D1F1-432D-891D-47DE205BD2E4Q28731698-2BB4292C-3739-43EE-9093-BC3318096D37Q33861946-0B70182D-BC47-48A1-915E-C9B02846F52CQ34442240-777C4CF7-55A3-41A6-86BF-2C7F88E8EE26Q34963939-61920F4F-96EC-4F9E-82AF-AB03E0985A4DQ35037212-C789DEB3-C3C9-4466-A0C5-FB76F5F53705Q35151097-A81EC318-C6F7-4A11-B201-2AEFC3F30663Q35892741-E98E6C3C-114B-48BC-BC46-99D6720F3620Q36056795-FD16773B-CAE7-43AB-8CB5-5E47D0D1EDDAQ36164564-C864C39E-8830-44C8-B882-47A0E373811EQ36314030-FD8B92BD-540E-4B0D-8886-EBAE6E1650E2Q36965861-91221954-A00F-4592-86F0-D8D836129FA8Q36997098-7ACF21B5-809C-421E-8F06-794405BE0D77Q37350672-875D1E48-DA9A-425D-AEF8-5968E2BFECB6Q37358557-EB735F4B-26ED-4139-8CEA-A6C92A5E9217Q37701042-6A7CDF9F-98FE-4573-B8CD-9F5A3D7D682BQ38714486-1A6C2FA9-0D23-4DDE-AB7A-8C07ECF3367EQ42488931-3B18F76F-4117-42BD-BEDF-981D04B884A4Q44793037-49C854AF-BA07-4089-80AB-E03122A5A712Q44836739-3C16A726-024D-4C0D-88A6-4069F194BE77Q44843756-1BED9F5F-A224-49EA-9D4F-23D976ABFE4BQ46465939-8034B12A-AAF8-46A1-B676-6E1BFD6387BDQ46720638-3ECA8CFD-B0A9-4EEA-8495-3F1D76FDFF68Q47350100-66273D33-631E-4CDD-8A05-80FC781602DCQ48249154-04B11BF3-CE75-4166-8618-5B0BD9B52D19Q48777493-80ED8A6B-7237-4237-B77F-9655DACEE76DQ50079750-EE3864D4-4742-4A91-BED2-5BCEA6923EBAQ79331450-B93C5954-907C-4694-A999-06268B65DC9BQ82616795-875297B5-1BC0-4A21-96A5-821613576F5CQ83509271-A83D3B2F-C045-4AEB-A41B-53167E997F25Q89018408-88467E53-7EB7-4E1D-BF64-BBDB764C5CBE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William G Frankle
@ast
William G Frankle
@en
William G Frankle
@es
William G Frankle
@nl
type
label
William G Frankle
@ast
William G Frankle
@en
William G Frankle
@es
William G Frankle
@nl
prefLabel
William G Frankle
@ast
William G Frankle
@en
William G Frankle
@es
William G Frankle
@nl
P106
P31
P496
0000-0003-0356-4197